Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | WDR5 | P61964 | 3/20 | 0.48 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | FASN | P49327 | 2/20 | 0.48 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582664 | 0.98 | KMT2A (0.49) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL8503283 | 0.94 | LMNA (0.47) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL8503846 | 0.91 | KMT2A (0.58) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL2983762 | 0.91 | CYP2C9 (0.48) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL2995801 | 0.90 | CYP2C9 (0.48) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL2984374 | 0.90 | CYP2C9 (0.48) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL15797364 | 0.90 | KMT2A (0.49) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL13361069 | 0.90 | KMT2A (0.47) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| SCHEMBL13360944 | 0.90 | KMT2A (0.47) | CYP2C9KMT2ALMNAWDR5ENGASE | |
| Lansoprazole SCHEMBL14482089 | 0.90 | CYP2C9 (0.57) | CYP2C9KMT2ALMNAWDR5ENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143409-B2 | X ray powder diffraction peaks at 10.5, 18.0, 18.4, 19.4, 21.1, 21.7, 22.9, 23.3, 27.1 and 31.6; easy handling and storage; bioavailability, release times, solubility | DIPHARMA FRANCIS S.R.L. (IT) | 2012-03-27 | — | — | US | disclosed |
| US-8143409-B2 | X ray powder diffraction peaks at 10.5, 18.0, 18.4, 19.4, 21.1, 21.7, 22.9, 23.3, 27.1 and 31.6; easy handling and storage; bioavailability, release times, solubility | DIPHARMA FRANCIS S.R.L. (IT) | 2012-03-27 | — | — | US | disclosed |
| US-20080161359-A1 | CRYSTALLINE FORM OF RABEPRAZOLE SODIUM | DIPHARMA FRANCIS S.R.L. (IT) | 2008-07-03 | — | — | US | disclosed |
| US-20080161359-A1 | CRYSTALLINE FORM OF RABEPRAZOLE SODIUM | DIPHARMA FRANCIS S.R.L. (IT) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161359-A1 | CRYSTALLINE FORM OF RABEPRAZOLE SODIUM | RAB35, RAB29, RABL3 | CYP2C9 54/4885KMT2A 3839/4885LMNA 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.